Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRGO 
Perrigo Company PLC (PRGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: PRGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.25
1 Year Target Price $34.25
| 1 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.54% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.92B USD | Price to earnings Ratio - | 1Y Target Price 34.25 |
Price to earnings Ratio - | 1Y Target Price 34.25 | ||
Volume (30-day avg) 5 | Beta 0.43 | 52 Weeks Range 20.52 - 29.92 | Updated Date 10/14/2025 |
52 Weeks Range 20.52 - 29.92 | Updated Date 10/14/2025 | ||
Dividends yield (FY) 5.38% | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.85% | Operating Margin (TTM) 6.43% |
Management Effectiveness
Return on Assets (TTM) 3.26% | Return on Equity (TTM) -1.32% |
Valuation
Trailing PE - | Forward PE 7.03 | Enterprise Value 6245159330 | Price to Sales(TTM) 0.67 |
Enterprise Value 6245159330 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 1.44 | Enterprise Value to EBITDA 10.21 | Shares Outstanding 137582814 | Shares Floating 136795840 |
Shares Outstanding 137582814 | Shares Floating 136795840 | ||
Percent Insiders 0.41 | Percent Institutions 106.91 |
Upturn AI SWOT
Perrigo Company PLC
Company Overview
History and Background
Perrigo Company PLC was founded in 1887 as a small-town general store in Allegan, Michigan. It evolved into a leading manufacturer and supplier of over-the-counter (OTC) self-care products and generic prescription products. Key milestones include expansion through acquisitions and strategic partnerships.
Core Business Areas
- Consumer Self-Care Americas (CSCA): Focuses on the manufacturing and distribution of OTC self-care products in the Americas.
- Consumer Self-Care International (CSCI): Focuses on the manufacturing and distribution of OTC self-care products outside of the Americas.
Leadership and Structure
The leadership team includes the CEO, CFO, and various vice presidents overseeing different business segments. The organizational structure is hierarchical, with distinct divisions for each core business area.
Top Products and Market Share
Key Offerings
- Allergy Relief Products: Includes loratadine, cetirizine, and fexofenadine. Competitors include Johnson & Johnson (ZYRTEC), Bayer (Claritin). Perrigo holds a significant market share in store-brand allergy relief products. Market share data is unavailable, but is a significant revenue driver.
- Pain Relief Products: Includes ibuprofen, acetaminophen, and naproxen. Competitors include Johnson & Johnson (TYLENOL), Bayer (Aleve). Perrigo holds a significant market share in store-brand pain relief products. Market share data is unavailable, but is a significant revenue driver.
- Infant Formula: Primarily store-brand infant formulas. Competitors include Abbott (Similac), Nestle (Gerber). Perrigo holds a significant market share in store-brand infant formulas. Market share data is unavailable, but is a significant revenue driver.
Market Dynamics
Industry Overview
The OTC self-care market is driven by aging populations, increasing healthcare costs, and a growing preference for self-medication. The generic prescription market is influenced by patent expirations and regulatory approvals.
Positioning
Perrigo is positioned as a leading provider of affordable OTC and generic prescription products, competing primarily on price and store-brand partnerships. Their competitive advantage lies in their scale and efficient manufacturing capabilities.
Total Addressable Market (TAM)
The global OTC market is estimated to be worth hundreds of billions of dollars. Perrigo is positioned to capture a portion of this TAM through its diversified product portfolio and strong relationships with retailers.
Upturn SWOT Analysis
Strengths
- Strong position in the store-brand market
- Diversified product portfolio
- Efficient manufacturing capabilities
- Established relationships with major retailers
Weaknesses
- Dependence on store-brand partnerships
- Exposure to price competition
- Vulnerability to regulatory changes
- Debt Levels
Opportunities
- Expanding into new markets
- Developing innovative OTC products
- Acquiring complementary businesses
- Growth of the self-care market
Threats
- Increased competition from branded products
- Changing consumer preferences
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- BAYRY
- ABT
- SNY
Competitive Landscape
Perrigo's advantages include its strong position in store brands and cost leadership. Disadvantages include less brand recognition compared to branded competitors.
Major Acquisitions
HRA Pharma
- Year: 2022
- Acquisition Price (USD millions): 2100
- Strategic Rationale: Expanded Perrigo's presence in key self-care categories and geographic regions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions, organic growth in OTC products, and expansion into new markets.
Future Projections: Analyst estimates for future growth vary depending on market conditions, regulatory changes, and company-specific initiatives. Financial websites like Yahoo Finance or Bloomberg provide analyst consensus estimates.
Recent Initiatives: Recent initiatives include product innovation, cost-cutting measures, and strategic acquisitions to expand the product portfolio.
Summary
Perrigo is a significant player in the OTC self-care market, particularly with its strong store-brand presence. Its efficient manufacturing gives it an edge, but reliance on store brands is both a strength and a weakness. The company should capitalize on the growing self-care market while managing the pressure of strong competitors and regulatory changes. Strategic acquisitions will be a key path to future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news providers
- Market research reports
- Company investor relations
Disclaimers:
Data and analysis are based on publicly available information and are subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perrigo Company PLC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1991-12-16 | President, CEO & Director Mr. Patrick Lockwood-Taylor | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8379 | Website https://www.perrigo.com |
Full time employees 8379 | Website https://www.perrigo.com | ||
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.